Systemic Anti-Cancer Therapy Regimen Library
PCN MM Relapsed - carfilzomib, pomalidomide and dexamethasone
Treatment Overview
Cycle 1 - 28 days - carfilzomib starting dose
dexamethasone: Consider dose reduction of dexamethasone to 20 mg ONCE a week in older or frail patients.
Cycles 2 to 12 - 28 days
dexamethasone: Consider dose reduction of dexamethasone to 20 mg ONCE a week in older or frail patients.
carfilzomib: For cycle 2 and further cycles, consider increasing carfilzomib dose to 70 mg/m2 (cap dose at: 154 mg) IV days 1, 8 and 15, according to response and if tolerated.
Cycle 13 (and all further cycles) - 28 days - carfilzomib Q2W
dexamethasone: Consider dose reduction of dexamethasone to 10 mg ONCE a week in older or frail patients.
carfilzomib: For cycle 2 and further cycles, consider increasing carfilzomib dose to 70 mg/m2 (cap dose at: 154 mg) IV days 1 and 15, according to response and if tolerated.
Cycle details
Cycle 1 - 28 days - carfilzomib starting dose
Medication | Dose | Route | Days | Max Duration |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration | 1 to 21 | |
dexamethasone * | 40 mg flat dosing | oral administration | 1, 8, 15, 22 |
|
sodium chloride | 0.9 % | intravenous | 1, 8, 15 | 30 minutes |
carfilzomib * | 20 mg/m² Cap dose per administration at: 44 mg | intravenous | 1 | 30 minutes |
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 8, 15 | 30 minutes |
dexamethasone: Consider dose reduction of dexamethasone to 20 mg ONCE a week in older or frail patients.
Cycles 2 to 12 - 28 days
Medication | Dose | Route | Days | Max Duration |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration | 1 to 21 | |
dexamethasone * | 40 mg flat dosing | oral administration | 1, 8, 15, 22 |
|
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 1, 8, 15 | 30 minutes |
dexamethasone: Consider dose reduction of dexamethasone to 20 mg ONCE a week in older or frail patients.
carfilzomib: For cycle 2 and further cycles, consider increasing carfilzomib dose to 70 mg/m2 (cap dose at: 154 mg) IV days 1, 8 and 15, according to response and if tolerated.
Cycle 13 (and all further cycles) - 28 days - carfilzomib Q2W
Medication | Dose | Route | Days | Max Duration |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration | 1 to 21 | |
dexamethasone * | 20 mg flat dosing | oral administration | 1, 15 | |
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 1, 15 | 30 minutes |
dexamethasone: Consider dose reduction of dexamethasone to 10 mg ONCE a week in older or frail patients.
carfilzomib: For cycle 2 and further cycles, consider increasing carfilzomib dose to 70 mg/m2 (cap dose at: 154 mg) IV days 1 and 15, according to response and if tolerated.
Full details
Cycle 1 - 28 days - carfilzomib starting dose
Day: 1
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
|
dexamethasone * | 40 mg flat dosing | oral administration |
Instructions:
30 minutes to 4 hours prior to carfilzomib with food.
|
|
sodium chloride | 0.9 % | intravenous | 30 minutes |
Quantity:250 mL
Instructions:
Prior to carfilzomib infusion.
|
carfilzomib * | 20 mg/m² Cap dose per administration at: 44 mg | intravenous | 30 minutes |
Day: 2
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 3
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 4
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 5
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 6
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 7
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 8
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
|
dexamethasone * | 40 mg flat dosing | oral administration |
Instructions:
30 minutes to 4 hours prior to carfilzomib with food.
|
|
sodium chloride | 0.9 % | intravenous | 30 minutes |
Quantity:250 mL
Instructions:
Prior to carfilzomib infusion.
|
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 30 minutes |
Day: 9
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 10
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 11
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 12
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 13
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 14
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 15
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
|
dexamethasone * | 40 mg flat dosing | oral administration |
Instructions:
30 minutes to 4 hours prior to carfilzomib with food.
|
|
sodium chloride | 0.9 % | intravenous | 30 minutes |
Quantity:250 mL
Instructions:
Prior to carfilzomib infusion.
|
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 30 minutes |
Day: 16
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 17
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 18
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 19
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 20
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 21
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 22
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
dexamethasone * | 40 mg flat dosing | oral administration |
Instructions:
Take in the morning with food.
|
Cycles 2 to 12 - 28 days
Day: 1
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
|
dexamethasone * | 40 mg flat dosing | oral administration |
Instructions:
30 minutes to 4 hours prior to carfilzomib with food.
|
|
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 30 minutes |
Instructions:
Consider increasing dose to 70 mg/m2 (cap dose at: 154 mg) according to response and if tolerated. |
Day: 2
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 3
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 4
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 5
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 6
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 7
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 8
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
|
dexamethasone * | 40 mg flat dosing | oral administration |
Instructions:
30 minutes to 4 hours prior to carfilzomib with food.
|
|
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 30 minutes |
Instructions:
Consider increasing dose to 70 mg/m2 (cap dose at: 154 mg) according to response and if tolerated. |
Day: 9
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 10
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 11
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 12
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 13
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 14
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 15
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
|
dexamethasone * | 40 mg flat dosing | oral administration |
Instructions:
30 minutes to 4 hours prior to carfilzomib with food.
|
|
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 30 minutes |
Instructions:
Consider increasing dose to 70 mg/m2 (cap dose at: 154 mg) according to response and if tolerated. |
Day: 16
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 17
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 18
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 19
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 20
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 21
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 22
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
dexamethasone * | 40 mg flat dosing | oral administration |
Instructions:
Take in the morning with food.
|
Cycle 13 (and all further cycles) - 28 days - carfilzomib Q2W
Day: 1
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
|
dexamethasone * | 20 mg flat dosing | oral administration |
Instructions:
Take in the morning with food 30 minutes to 4 hours prior to carfilzomib.
|
|
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 30 minutes |
Instructions:
Consider increasing dose to 70 mg/m2 (cap dose at: 154 mg) according to response and if tolerated. |
Day: 2
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 3
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 4
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 5
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 6
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 7
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 8
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 9
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 10
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 11
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 12
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 13
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 14
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 15
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
|
dexamethasone * | 20 mg flat dosing | oral administration |
Instructions:
Take in the morning with food 30 minutes to 4 hours prior to carfilzomib.
|
|
carfilzomib * | 56 mg/m² Cap dose per administration at: 123 mg | intravenous | 30 minutes |
Instructions:
Consider increasing dose to 70 mg/m2 (cap dose at: 154 mg) according to response and if tolerated. |
Day: 16
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 17
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 18
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 19
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 20
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Day: 21
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
pomalidomide | 4 mg Once daily | oral administration |
Instructions:
Additional details:
|
Additional details
Section 1: Teratogenic effects
All patients must fulfil the requirements of the pregnancy prevention risk management programme to ensure pregnant women are not exposed to pomalidomide.
Supportive Care Factors
Factor | Value |
---|---|
Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis recommended |
Emetogenicity: | Variable |
Gastroprotection: | Gastroprotection may be considered |
Hydration: | Variable |
Hypersensitivity / Infusion related reaction risk: | High - routine premedication recommended |
Pneumocystis jirovecii pneumonia (PJP) prophylaxis: | Routine antibiotic prophylaxis recommended |
Thromboprophylaxis: | Thromboprophylaxis is recommended |
Tumour lysis syndrome prophylaxis: | Tumour lysis syndrome prophylaxis may be considered |
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
Emetogenicity: LOW - carfilzomib; MINIMAL to LOW - pomalidomide alone.
References
Amgen (New Zealand) Limited Kyprolis New Zealand Datasheet 4 December 2020 https://www.medsafe.govt.nz/profs/datasheet/k/kyprolisinf.pdf (Accessed 31 March 2022).
Celegene Limited. Pomalyst New Zealand Datasheet 31 January 2022. https://www.medsafe.govt.nz/profs/datasheet/p/pomalystcap.pdf (Accessed 30 July 2022).
Regimen details sometimes vary slightly from the published literature after recommendation by expert committee consensus.
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.